Genmab — August 2017
-
Danske Banks seneste analyse: Tisotumab. 25% sandsynlighed for lancering i 2022. NPV per aktie 60 DKK.
-
1449
-
lidt i underkanten efter en validering af Tiso Vedotin, men hvad fanden
-
-
Vi skal helst lande over 1.440 for at få bekræftet trendskiftet.
-
yup
-
-
Helge er blevet fan af Heystocks
-
Jeg følger Heystocks. Den kan jeg bedre lide.
-
1440
-
ja legolas ramte plet
-
Aktieekspert: Flere selskaber kan være ude efter Genmab
En britisk aktieekspert, som for nylig forudsagde et opkøbstilbud på Nets før alle andre, mener at vide, at flere store medicinalselskaber kan være interesserede i at opkøbe Genmab.
(medwatch.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind